A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
NCT06299124
·
clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Advanced Solid Tumor
Interventions
DRUG:
RGT-419B
Sponsor
Regor Pharmaceuticals Inc.